Roche Holding AG (FRA:RHO5)

Market Cap	321.31B +31.5%
Revenue (ttm)	68.05B +1.5%
Net Income	13.83B +55.6%
EPS	17.23 +55.6%
Shares Out	n/a
PE Ratio	23.23
Forward PE	18.02
Dividend	10.18 (2.53%)
Ex-Dividend Date	Mar 27, 2025

Volume	511
Average Volume	342
Open	401.35
Previous Close	403.65
Day's Range	398.75 - 402.70
52-Week Range	259.15 - 407.10
Beta	n/a
RSI	69.71
Earnings Date	Jan 29, 2026

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir...

• Industry: Pharmaceutical Preparations
• Founded: 1896
• Employees: 103,249
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RHO5

Financial Performance

In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.

Financial numbers in CHF